TrialThe oncologist2018

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.

Joachim von Pawel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.